The specter of generic rivalry has repeatedly loomed around copyright’s famous drug, Sildenafil, triggering questions about the outlook of related medicinal portfolios. While first years saw impressive returns, the patent end has created the way for less expensive substitutes, likely diminishing profitability and posing a real risk for stakeholde